Lincoln Pharmaceuticals Q4FY24 results. Profits rise y-o-y and Q-o-Q, but margins contract. Waiting for management commentary on results before deciding whether to exit or hold.
Posts in category Value Pickr
Skipper Ltd., (Power and Water) a moat in making? (16-05-2024)
Here is a good article related to new Transmission line and power grid policy of America.Renewables Will Skyrocket Under New Transmission Policies Renewables Will Skyrocket Under New Transmission Policies
Beta Drugs Limited (16-05-2024)
Q4FY24 Concall highlights:
- Ebidta declined due to high RM cost (platin which is a gold n platinum derivative)
- Platin cost comprises 14-15% sales
- Platin can’t be manufactured in house.
- Yearly sales breakup:
- Branded: 89 Cr (margin 33-36%)
- CDMO: 140 Cr (margin 15-17%)
- Exports: 46 Cr (margin 28-32%)
- API : 21 Cr (margin 22-23%)
- Derma: 6.83 Cr - halfyearly sales breakup:
- Branded: 41.5 Cr
- CDMO: 68 Cr
- Export: 30 Cr
- API: 11 Cr
- Derma: 3.3 Cr - Ebidta will try to bring to 26% in FY25
- Cosmotology:
- division posted net loss
- guidance FY25 min sales 14-15 Cr
- gross margin is 65%
- plant setup initiate by Fy25-26 ( 30 - 35 Cr)
- recently launched 5 products (haircare, sunscreen, moisturizer)
- Will focus on hair product segment
- Future target 35% of business
- Dr prescribed medicine after Dr approves. - Cleared audit n received registration cert from Urasia
- Cytotoxic syrup facility started
- Own brand, injectable: Oral = 43 : 57
- FY25 guidance 25-30% sales.
- 70% Api in house manufactured.
- 2-3 months will migrate to main board, process already initiated.
- export business target 35% business in future.
Amoul Portfolio (16-05-2024)
What made you choose AR over Nuvama?
Chirag’s Portfolio (16-05-2024)
Hi, could you please share the conviction behind starhealth in your portfolio?
Aarti Pharma Labs (16-05-2024)
A few good key takeaways from the call of Aarti Pharma - (Q4 - FY24)
The company operates in 3 segments:
-
Zine derivatives (44% of Q4 revenue)
-
API and Intermediates (37.6% of Q4 revenue)
-
CDMO/CMO (18.4% of Q4 revenue)
Q4 FY24 saw highest highest-ever quarterly net profit
Consolidated revenue grew 23% QoQ and 47% YoY in Q4
For FY25, expect revenue growth of 10-12%
Major expansion plans:
Brownfield expansion of Zine capacity from 5,000 to 9,000 MT (capex ~Rs. 130-180 cr)
New API/Intermediates plant at Atali (capex ~Rs. 375 cr)
Setting up solar power plant (capex ~Rs. 80-90 cr) Total capex for FY25 expected at ~Rs. 600 cr
CDMO/CMO business is seeing strong growth, working with 16 innovators on 40 projects currently
My Investment Journey & Philosophy (16-05-2024)
Hi All,
I started my investment journey in January 2021 with the idea of actively buying stocks with a set amount each month. During the initial phase, everything was going well as it was a good bull run. Every pick I made seemed to be performing well until a point where the stocks became stagnant. This realization prompted me to put more effort into finding good companies that will perform well going forward.
I’ve provided my reasons for holding certain stocks in my portfolio, but I’m interested in hearing your perspective.
BERGEPAINT
This company has excellent management and is a strong player in the paint industry. However, the entire paint sector is currently slow, and the entry of new competitors are two factors contributing to the stock’s underperformance. As a result, I am experiencing a 12.16% loss in this stock.
BORORENEW
Bororenew is engaged in the manufacturing of low iron textured solar glass for use in photovoltaic panels and is the only solar glass manufacturer in India. As the world moves towards clean energy and solar power, this company is poised to play a significant role. The only issue with this company is the imposition of antidumping duties. I am holding this stock from lower levels.
BSE
The only listed exchange, BSE, has been the standout performer in my portfolio.
CDSL
The only listed depository, CDSL, is a key holding in my portfolio. I am holding it because it operates in a duopoly market.
EXIDEIND
Exide Industries holds a significant market share in the battery segment and has the first-mover advantage in Li-ion batteries as EVs and related technologies are becoming the future. The stock has recently started aligning with the company’s performance and growth story.
GPIL
This company has been excellent for me in terms of both financial performance and management execution. They are doing well with their business.
GUJGASLTD
Considering Gujarat Gas’s simple business model and limited growth prospects, I am planning to sell the share.
IEX
Holding this company since it was the monopolistic, and before the government interference, I feel this will jump back once the dust settles.
INFY
I would say Infosys for me was an accidental buy. I didn’t want to jump into large-cap, and that too in the IT sector. Once I clear up my losses, I am planning to sell this.
PRAJIND
Good Company run by excellent management.
PRICOL
This company is an interesting pick as it works as a proxy for the automotive sector.
PRINCEPIPE
Considering the growth story of India, we cannot write off the pipe sector, as it plays a significant role. Princepipe has a good story, and recently they included bath wares in their portfolio, which looks interesting.
RELIANCE
Reliance being the story of India.
TATAMOTORS
I bought this share because the Tata brand is synonymous with trust, and Tata Motors has been an excellent story of comeback and perseverance.
TATAPOWER
Being a major player in the power sector and the entire EV space, TATAPOWER holds a strategic position in two crucial industries shaping the future.
TATASTEEL
Tata Steel holds the position of being the biggest player in the steel industry space has significant influence and market presence.
TATATECH
I got this share as part of the IPO, always looking intresting Would like to buy it back when it’s in good levels again.
Philosophy
- I prefer companies that are not excessively large in size.
- I look for management teams that are actively interested in driving growth.
- I seek investments in dynamic sectors with growth opportunities.
- I prioritize companies with a positive profit and loss statement.
- I prefer companies that are either debt-free or have negligible debt, depending on the sector.
So my question boil down to following.
- Is it okay to ignore valuations when you have a growth story in place?
- Is the strategy discussed so far reasonable enough to get me an average return of 19% YoY?
- Should I consider doing small profit bookings in between, or keep it all for the next decade?
- If you have a different viewpoint on the above-mentioned companies for the long run, please share?
Mayank portfolio (16-05-2024)
Because of valuation but also thick anand rathi is better business them nuvama
Mayank portfolio (16-05-2024)
Any reason you choose NUVAMA over anand rathi in wealth management space?
Premco Global — Narrow Fabric (A critical component for inner wear) (16-05-2024)
Since standalone are inferior in profitability as compared with Consolidated, I infer that Vietnam operations did well during the quarter. Also, around Rs 1 Cr for FY24 has been capitalised as Capital WIP for Umargao plant as per notes. Assuming that plant would be operational from FY25, we shall see further increase in fixed overhead (Depreciation+ Increased expenditure of new plant), which would also likely to adversely impact company performance in domestic market. In order to stock to see major movement, it would need major improvement in domestic market, stable Vietnam market and good capital allocation decision like Buyback and listing of stock on NSE. For last decade the company has delivered on any of these. Hence, not expecting any magical swing in the stock price.
Discl: My view may biased due to my holding. I am not SEBI registered advisor. Not suggesting any investment action. I may exit/change my holding without informing forum.